Shared on07 Aug 25Fair value Decreased 26%
Despite a modestly improved revenue growth outlook and a significantly lower forward P/E, consensus analyst sentiment has worsened, leading to a marked price target reduction from $0.96 to $0.714. What's in the News Adaptimmune Therapeutics reached a settlement with MD Anderson Cancer Center to resolve litigation related to a previous strategic alliance, with all claims to be dismissed upon payment.
Shared on30 Jul 25Fair value Decreased 43%
Despite improved revenue growth forecasts and a lower future P/E ratio reflecting better earnings expectations, analysts have significantly reduced the fair value for Adaptimmune Therapeutics, as indicated by the consensus price target dropping from $1.67 to $0.96. What's in the News Adaptimmune settled litigation with MD Anderson regarding a breach of contract under a 2016 alliance, agreeing to a financial settlement the company deems immaterial to its financial position or results.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 23.6x to 26.4x.
Shared on09 Apr 25Fair value Decreased 1.76%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.